ATE424414T1 - Chimere somatostatin-dopamin-analoga - Google Patents
Chimere somatostatin-dopamin-analogaInfo
- Publication number
- ATE424414T1 ATE424414T1 AT02734699T AT02734699T ATE424414T1 AT E424414 T1 ATE424414 T1 AT E424414T1 AT 02734699 T AT02734699 T AT 02734699T AT 02734699 T AT02734699 T AT 02734699T AT E424414 T1 ATE424414 T1 AT E424414T1
- Authority
- AT
- Austria
- Prior art keywords
- chimers
- somatostatin
- dopamine analogue
- dopamine
- analogue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
- C07D457/12—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29705901P | 2001-06-08 | 2001-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE424414T1 true ATE424414T1 (de) | 2009-03-15 |
Family
ID=23144680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02734699T ATE424414T1 (de) | 2001-06-08 | 2002-06-07 | Chimere somatostatin-dopamin-analoga |
Country Status (25)
Country | Link |
---|---|
US (4) | US7579435B2 (de) |
EP (2) | EP1401863B1 (de) |
JP (2) | JP3996897B2 (de) |
KR (3) | KR100620435B1 (de) |
CN (2) | CN101481405A (de) |
AR (1) | AR037226A1 (de) |
AT (1) | ATE424414T1 (de) |
AU (1) | AU2002305845B2 (de) |
BR (1) | BR0210915A (de) |
CA (1) | CA2449634C (de) |
CZ (1) | CZ305160B6 (de) |
DE (1) | DE60231403D1 (de) |
DK (2) | DK2062914T3 (de) |
ES (2) | ES2325880T3 (de) |
HK (1) | HK1060360A1 (de) |
HU (1) | HUP0400245A3 (de) |
IL (2) | IL158922A0 (de) |
MX (1) | MXPA03011321A (de) |
NO (2) | NO332042B1 (de) |
NZ (1) | NZ530007A (de) |
PL (1) | PL216217B1 (de) |
PT (2) | PT1401863E (de) |
RU (1) | RU2277539C2 (de) |
TW (1) | TWI318214B (de) |
WO (1) | WO2002100888A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04002621A (es) * | 2001-09-21 | 2004-07-08 | Univ Tulane | Conjugados de analogos de somatostatina o bombesina para diagnostico o terapeuticos y usos de los mismos. |
EP1617856B1 (de) * | 2003-04-11 | 2014-01-15 | Ipsen Pharma | Chimere somatostatin-dopamin-analoga |
AU2008200693B2 (en) * | 2003-04-11 | 2010-07-08 | Ipsen Pharma S.A.S. | Treatment of disease or condition with somatostatin-dopamine chimeric analogs |
US8709998B2 (en) * | 2003-04-22 | 2014-04-29 | Ipsen Pharma S.A.S. | Peptide vectors |
DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
EP1874283A4 (de) * | 2005-04-28 | 2011-11-02 | Ferring Bv | Verwendung neuer verbindungen zur behandlung von ibd |
US9098855B2 (en) * | 2006-05-23 | 2015-08-04 | Intelligent Clearing Network, Inc. | Intelligent clearing network |
EP2296687A4 (de) * | 2008-05-14 | 2012-12-26 | Ipsen Pharma Sas | Pharmazeutische zusammesetzungen von somatostatin-dopamin-konjugaten |
FR2949469A1 (fr) * | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
WO2011104627A1 (en) * | 2010-02-24 | 2011-09-01 | Ipsen Pharma S.A.S. | Metabolites of dop2-d-lys(dop2)-cyclo[cys-tyr-d-trp-lys-abu-cys]-thr-nh2 |
JP6113144B2 (ja) * | 2011-04-21 | 2017-04-12 | セラテクノロジーズ・インコーポレーテッド | 成長ホルモン放出因子(grf)類似体およびその使用 |
RU2625793C2 (ru) | 2011-12-23 | 2017-07-19 | Ипсен Мэньюфэкчеринг Айэлэнд Лимитед | Способ синтеза терапевтических пептидов |
US9620430B2 (en) | 2012-01-23 | 2017-04-11 | Taiwan Semiconductor Manufacturing Company, Ltd. | Sawing underfill in packaging processes |
TWI523863B (zh) | 2012-11-01 | 2016-03-01 | 艾普森藥品公司 | 體抑素-多巴胺嵌合體類似物 |
WO2014070965A2 (en) | 2012-11-01 | 2014-05-08 | Ipsen Pharma S.A.S | Somatostatin analogs and dimers thereof |
AU2013355391B2 (en) * | 2012-12-03 | 2017-08-03 | The Board Of Regents Of The University Of Oklahoma | Peptide compounds and methods of production and use thereof |
US9096679B2 (en) | 2012-12-03 | 2015-08-04 | The Board Of Regents Of The University Of Oklahoma | Peptide compounds and methods of production and use thereof |
US20200157159A1 (en) | 2013-04-16 | 2020-05-21 | The Board Of Regents Of The University Of Oklahoma | Peptide compounds and compositions thereof |
PL3166967T3 (pl) | 2014-09-14 | 2023-07-24 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Syntetyczne ligandy receptora somatostatyny |
US9657020B2 (en) | 2015-01-20 | 2017-05-23 | Xoc Pharmaceuticals, Inc. | Ergoline compounds and uses thereof |
BR112017015510A2 (pt) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo |
CA3064274A1 (en) | 2017-06-01 | 2018-12-06 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
WO2023225043A1 (en) * | 2022-05-18 | 2023-11-23 | Kuleon Llc | Tricyclic and tetracyclic serotonin receptor modulators and methods of making and using the same |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2589978A (en) * | 1952-03-18 | Lysergyl and isolysergyl glycines | ||
US2619488A (en) * | 1952-11-25 | Method of preparing d | ||
DE140044C (de) | ||||
FR98F (de) | 1961-05-29 | |||
AT258479B (de) * | 1961-05-29 | 1967-11-27 | Farmaceutici Italia | Verfahren zur Herstellung von neuen Verbindungen aus der Klasse des D-6-Methyl- (und -1,6-Dimethyl)-8-amino-methyl-ergolins I |
US3966941A (en) * | 1970-09-23 | 1976-06-29 | Spofa United Pharmaceutical Works | Composition for preventing lactation or pregnancy in mammals and the method for using the same |
US3901894A (en) | 1974-06-06 | 1975-08-26 | Lilly Co Eli | 8-thiomethylergolines |
US4291022A (en) | 1975-03-11 | 1981-09-22 | Sandoz Ltd. | Organic compounds |
HU172479B (hu) * | 1976-03-09 | 1978-09-28 | Gyogyszerkutato Intezet | Sposob poluchenija novykh soedinenij s ehrgolenovymi i |
US4133782A (en) | 1976-06-07 | 1979-01-09 | The Salk Institute For Biological Studies | Somatostatin analogs with dissociated biological activities |
US4190575A (en) | 1977-12-27 | 1980-02-26 | American Home Products Corporation | Polypeptides related to somatostatin |
EP0000053B1 (de) | 1977-06-08 | 1981-05-27 | Merck & Co. Inc. | Somatostatin-ähnliche Verbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten |
US4357259A (en) | 1977-08-01 | 1982-11-02 | Northwestern University | Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres |
US4211693A (en) | 1977-09-20 | 1980-07-08 | The Salk Institute For Biological Studies | Peptides with para-substituted phenylalanine |
LU78191A1 (de) | 1977-09-28 | 1979-05-25 | Ciba Geigy Ag | Verfahren zur herstellung von neuen cyclopeptiden |
US4166182A (en) | 1978-02-08 | 1979-08-28 | Eli Lilly And Company | 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds |
CA1107273A (en) | 1978-05-19 | 1981-08-18 | Chester A. Meyers | Somatostatin analogs having a substituted tryptophyl residue in position eight |
JPS5819669B2 (ja) | 1978-10-28 | 1983-04-19 | 白井松新薬株式会社 | 新規生理活性ペプチド化合物及びその製造法 |
DD140044A1 (de) * | 1978-11-08 | 1980-02-06 | Guenter Losse | Verfahren zur herstellung von lysergyl-enkephalin-derivaten |
US4215039A (en) | 1979-02-15 | 1980-07-29 | American Home Products Corporation | Somatostatin analogues |
US4190648A (en) | 1979-03-13 | 1980-02-26 | Merck & Co., Inc. | Peptides having somatostatin activity |
US4316890A (en) | 1979-03-16 | 1982-02-23 | Ciba-Geigy Corporation | Peptides and processes for the manufacture thereof |
US4209426A (en) | 1979-05-29 | 1980-06-24 | American Home Products Corporation | Polypeptides related to somatostatin |
US4328214A (en) | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
ATE2512T1 (de) | 1979-11-27 | 1983-03-15 | Sandoz Ag | Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung. |
US4369179A (en) | 1979-12-14 | 1983-01-18 | Ciba-Geigy Corporation | Acylpeptides |
US4358439A (en) | 1979-12-21 | 1982-11-09 | Ciba-Geigy Corporation | Cyclooctapeptides |
US4282143A (en) | 1980-06-13 | 1981-08-04 | American Home Products Corporation | Octapeptides lowering growth hormone |
US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
DK81082A (da) | 1981-03-06 | 1982-09-07 | Sandoz Ag | Fremgangsmaade til fremstilling af polypeptider |
US4360516A (en) | 1981-04-13 | 1982-11-23 | Merck & Co., Inc. | Modified D-retro cyclic hexapeptide somatostatin analogs |
GB2103603B (en) * | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
GB2112382B (en) | 1981-11-06 | 1985-03-06 | Erba Farmitalia | Ergoline derivatives |
EP0083305B1 (de) | 1981-12-24 | 1985-07-10 | Ciba-Geigy Ag | Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung |
FR2522655B1 (fr) | 1982-03-05 | 1987-03-06 | Sanofi Sa | Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant |
PH21123A (en) | 1983-04-28 | 1987-07-27 | Erba Farmitalia | Ergoline derivatives |
US4486415A (en) | 1983-08-15 | 1984-12-04 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4485101A (en) | 1983-10-11 | 1984-11-27 | Administrators Of The Tulane Educational Fund | Peptides |
US4522813A (en) | 1983-10-27 | 1985-06-11 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
HUT42101A (en) | 1985-01-07 | 1987-06-29 | Sandoz Ag | Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds |
US4725577A (en) | 1985-04-25 | 1988-02-16 | Administrators Of The Tulane Educational Fund | Biologically active lysine containing octapeptides |
US4650787A (en) | 1985-04-25 | 1987-03-17 | Schally Andrew Victor | Biologically active octapeptides |
US4585755A (en) | 1985-04-29 | 1986-04-29 | Merck & Co., Inc. | Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents |
US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
HU206890B (en) | 1986-10-13 | 1993-01-28 | Sandoz Ag | Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components |
US4871717A (en) | 1987-01-07 | 1989-10-03 | Administrators Of The Tulane Educational Fund | Peptides |
DE3845000C2 (de) * | 1987-07-10 | 1998-11-19 | Novartis Ag | Anwendung von Octreotid zur Behandlung von Brustkrebs |
EP0329295A1 (de) | 1988-02-01 | 1989-08-23 | The Upjohn Company | Renin inhibierende Peptide mit polaren Endgruppen |
GB8813339D0 (en) * | 1988-06-06 | 1988-07-13 | Sandoz Ltd | Improvements in/relating to organic compounds |
DK375789A (da) | 1988-08-18 | 1990-02-19 | Syntex Inc | Peptidderivater |
CA2012115C (en) | 1989-03-15 | 2001-07-03 | Biomeasure, Inc. | Iodinated somatostatins |
JP2882679B2 (ja) | 1989-04-26 | 1999-04-12 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | 線状ソマトスタチン類似体 |
US5621133A (en) * | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
HU203549B (en) | 1989-06-27 | 1991-08-28 | Richter Gedeon Vegyeszet | New stereoselektive hydrogenating process for producing dihydro-lisergol |
HUT59166A (en) | 1989-12-08 | 1992-04-28 | Univ Tulane | Process for producing octqpeptide somatostatine analogues with treonine at the 6 position and pharmaceutical compositions containing them |
US5411966A (en) * | 1990-01-15 | 1995-05-02 | Schering Aktiengesellschaft | 2, 13-disubstituted ergolines, their production and use in pharmaceutical agents |
DK0464178T3 (da) | 1990-01-25 | 1996-01-02 | Pharmacia Spa | Fremgangsmåde til fremstilling af ergolinderivater |
US5043341A (en) * | 1990-04-11 | 1991-08-27 | Eli Lilly And Company | N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides |
IT1240643B (it) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano |
EP0538395A4 (en) * | 1990-07-10 | 1993-06-16 | Synaptic Pharmaceutical Corporation | Nucleic acid sequences encoding a human dopamine d 1? receptor |
HU207104B (en) | 1991-01-25 | 1993-03-01 | Biosignal Kutato Fejlesztoe Kf | Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds |
WO1994004752A1 (en) | 1992-08-20 | 1994-03-03 | Industrial Progress, Inc. | Acid-to-alkaline papermaking process |
ATE204278T1 (de) * | 1992-12-24 | 2001-09-15 | Pharmacia & Upjohn Spa | Serotoninergische ergolin derivate |
FR2699923B1 (fr) | 1992-12-28 | 1995-03-17 | Great Lakes Chemical France | Copolymères d'esters gras insaturés, leur utilisation comme additif de viscosité et huile lubrifiante contenant lesdits copolymères. |
AU692435B2 (en) * | 1993-01-21 | 1998-06-11 | United States Of America, As Represented By The Secretary Of Agriculture, The | Vaccines and methods for preventing and treating fescue toxicosis in herbivo res |
MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
AU2582197A (en) * | 1996-03-15 | 1997-10-01 | Start Technology Partnership | Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression |
US5925618A (en) * | 1997-03-06 | 1999-07-20 | American Cyanamid Company | Peptides useful as somatostatin antagonists |
GB9711043D0 (en) * | 1997-05-29 | 1997-07-23 | Ciba Geigy Ag | Organic compounds |
DE19832191A1 (de) | 1998-07-17 | 2000-01-27 | Knoell Hans Forschung Ev | Neuartige Ergolinamin-Derivate und ihre Verwendung |
-
2002
- 2002-06-07 AT AT02734699T patent/ATE424414T1/de active
- 2002-06-07 EP EP02734699A patent/EP1401863B1/de not_active Expired - Lifetime
- 2002-06-07 DK DK08171319.0T patent/DK2062914T3/da active
- 2002-06-07 DE DE60231403T patent/DE60231403D1/de not_active Expired - Lifetime
- 2002-06-07 CN CNA2008101781440A patent/CN101481405A/zh active Pending
- 2002-06-07 ES ES02734699T patent/ES2325880T3/es not_active Expired - Lifetime
- 2002-06-07 KR KR1020037016005A patent/KR100620435B1/ko not_active IP Right Cessation
- 2002-06-07 PT PT02734699T patent/PT1401863E/pt unknown
- 2002-06-07 KR KR1020057022692A patent/KR100743212B1/ko not_active IP Right Cessation
- 2002-06-07 JP JP2003503654A patent/JP3996897B2/ja not_active Expired - Fee Related
- 2002-06-07 NZ NZ530007A patent/NZ530007A/en not_active IP Right Cessation
- 2002-06-07 AU AU2002305845A patent/AU2002305845B2/en not_active Ceased
- 2002-06-07 ES ES08171319.0T patent/ES2483722T3/es not_active Expired - Lifetime
- 2002-06-07 WO PCT/US2002/017859 patent/WO2002100888A1/en active Application Filing
- 2002-06-07 HU HU0400245A patent/HUP0400245A3/hu unknown
- 2002-06-07 PT PT81713190T patent/PT2062914E/pt unknown
- 2002-06-07 DK DK02734699T patent/DK1401863T3/da active
- 2002-06-07 US US10/479,771 patent/US7579435B2/en not_active Expired - Fee Related
- 2002-06-07 CN CNA028114647A patent/CN1514843A/zh active Pending
- 2002-06-07 CZ CZ2003-3122A patent/CZ305160B6/cs not_active IP Right Cessation
- 2002-06-07 BR BR0210915-8A patent/BR0210915A/pt not_active IP Right Cessation
- 2002-06-07 PL PL364457A patent/PL216217B1/pl unknown
- 2002-06-07 EP EP08171319.0A patent/EP2062914B1/de not_active Expired - Lifetime
- 2002-06-07 RU RU2004100109/04A patent/RU2277539C2/ru not_active IP Right Cessation
- 2002-06-07 CA CA2449634A patent/CA2449634C/en not_active Expired - Fee Related
- 2002-06-07 IL IL15892202A patent/IL158922A0/xx unknown
- 2002-06-07 MX MXPA03011321A patent/MXPA03011321A/es active IP Right Grant
- 2002-06-07 TW TW091112381A patent/TWI318214B/zh not_active IP Right Cessation
- 2002-06-07 KR KR1020067014785A patent/KR100754917B1/ko not_active IP Right Cessation
- 2002-06-10 AR ARP020102180A patent/AR037226A1/es unknown
-
2003
- 2003-12-02 NO NO20035358A patent/NO332042B1/no not_active IP Right Cessation
-
2004
- 2004-04-15 HK HK04102651.2A patent/HK1060360A1/xx not_active IP Right Cessation
-
2006
- 2006-05-15 US US11/434,273 patent/US7572883B2/en not_active Expired - Fee Related
-
2007
- 2007-02-26 JP JP2007044989A patent/JP4181203B2/ja not_active Expired - Fee Related
-
2009
- 2009-06-22 US US12/456,715 patent/US8178651B2/en not_active Expired - Fee Related
- 2009-10-01 IL IL201310A patent/IL201310A/en not_active IP Right Cessation
- 2009-10-07 US US12/587,452 patent/US8324386B2/en not_active Expired - Fee Related
-
2011
- 2011-08-26 NO NO20111165A patent/NO338459B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE424414T1 (de) | Chimere somatostatin-dopamin-analoga | |
ATE524462T1 (de) | C5-modifizierte indazolylpyrrolotriazine | |
DE50208022D1 (de) | Wischblatt | |
DE50206021D1 (de) | Schlauchklemme | |
DE50204386D1 (de) | Kreuztransducer | |
DE50103741D1 (de) | Welle-Nabe-Verbindung | |
DE50209238D1 (de) | Kugelgelenk | |
ATE335486T1 (de) | Hydrazono-malonitrile | |
DE50209410D1 (de) | Kugelgelenk | |
DE50204551D1 (de) | Kugelgelenk | |
DE50208372D1 (de) | Schrankaufhängevorrichtung | |
IS2523B (is) | Turn vindorkuvers | |
DE50203412D1 (de) | Schwenkkolbenverdränger | |
DE50204794D1 (de) | Kugelgelenk | |
DE50203984D1 (de) | Kugelgelenk | |
ATE355059T1 (de) | Isoxazolopyridinone | |
DE50208029D1 (de) | Kugelgelenk | |
DE60215562D1 (de) | Bogendruckmaschine | |
DE50201862D1 (de) | Messwandler | |
DE50203093D1 (de) | Losradlager | |
ATE319694T1 (de) | Phenylalkyne | |
ATA18372001A (de) | Gelenksbolzenbaueinheit | |
DE50209293D1 (de) | Amidpolymermasse | |
DE50207815D1 (de) | Kugelgelenk | |
DE50209386D1 (de) | Kugelgelenk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1401863 Country of ref document: EP |